The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImperial Innovations Group Regulatory News (IVO)

  • There is currently no data for IVO

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Notice of cancellation of admission to AIM

13 Nov 2017 07:00

RNS Number : 2415W
Touchstone Innovations PLC
13 November 2017
 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION

13 November 2017

Touchstone Innovations plc

 

Notice of cancellation of admission to trading on AIM

 

Further to the announcement released on 18 October 2017 by IP Group plc ("IP Group") declaring the IP Group offer (the "Offer") wholly unconditional in all respects, Touchstone Innovations plc ("Touchstone" or the "Company") notifies its shareholders that, at the request of IP Group, an application has been made to London Stock Exchange plc to cancel the trading facility in the ordinary shares in the capital of the Company ("Ordinary Shares") on AIM with effect from 7:00am on 11 December 2017.

The cancellation of trading in the Ordinary Shares will significantly reduce the liquidity and marketability of any Ordinary Shares and, as previously stated, the Board of Touchstone recommends that Touchstone shareholders who have not yet accepted the Offer now do so promptly.

Those Touchstone shareholders who accept the Offer will receive their new shares in IP Group as consideration for their Touchstone shares at an earlier date than they would as part of the compulsory acquisition procedure.

IP Group has announced that the Offer will remain open until further notice and that not less than 14 calendar days' notice will be given in respect of the closure of the Offer.

If you are a Touchstone shareholder and in any doubt as to the action you should take, you are recommended to seek your own financial advice immediately from your stockbroker, bank manager, solicitor, accountant, fund manager or other appropriate independent financial adviser authorised under the Financial Services and Markets Act 2000, as amended if you are resident in the United Kingdom or, if not, from another appropriately authorised independent financial adviser.

For further information contact:

Touchstone Innovations plc

020 3053 8834

Russ Cummings, Chief Executive Officer

William Rayner, General Counsel and Company Secretary

Jon Davies, Director of Communications

Instinctif Partners

020 7457 2020

Adrian Duffield/Mel Toyne-Sewell/Chantal Woolcock

J.P. Morgan Cazenove (Nominated adviser)

020 7742 4000

Michael Wentworth-Stanley/Alec Pratt

RBC Capital Markets (Joint Corporate Broker)

020 7653 4000

Marcus Jackson

 

Further Information

J.P. Morgan Limited, which conducts its UK investment banking business as J.P. Morgan Cazenove ("J.P. Morgan Cazenove"), is authorised and regulated in the United Kingdom by the Financial Conduct Authority. J.P. Morgan Cazenove is acting as financial adviser exclusively for Touchstone Innovations plc and no one else in connection with the matters set out in this announcement and will not regard any other person as its client in relation to the matters in this announcement and will not be responsible to anyone other than Touchstone Innovations plc for providing the protections afforded to clients of J.P. Morgan Cazenove or its affiliates, or for providing advice in relation to any matter referred to herein.

RBC Capital Markets is the business name used by RBC Europe Limited, which is authorised in the United Kingdom by the Prudential Regulation Authority ("PRA") and regulated by the Financial Conduct Authority and the PRA and is a subsidiary of the Royal Bank of Canada. RBC is acting as Corporate Broker to the Company.

 

Ends

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCEAPFEFDSXFFF
Date   Source Headline
30th May 20147:00 amRNSVeryan announces results on two-year Mimics study
22nd May 20147:00 amRNSYoyo closes £2.8 million seed investment round
6th May 20142:45 pmRNSHolding(s) in Company
24th Apr 20147:00 amRNSNexeon completes manufacturing facility
14th Apr 201412:00 pmRNSDirector change
3rd Apr 20143:36 pmRNSDirector's share purchase
28th Mar 20147:01 amRNSHalf Yearly Report
13th Mar 20141:04 pmRNSNotice of Results
13th Mar 20147:01 amRNSCircassia announces offer price
26th Feb 20147:40 amRNSCircassia indicative pricing notification
6th Feb 20147:03 amRNSCircassia announces intention to float
28th Jan 20147:00 amRNSAppointment of Joint Broker
7th Jan 20147:00 amRNSCell Medica achieves EU orphan drug designation
30th Dec 201310:00 amRNSFurther investment in TopiVert
18th Dec 20137:00 amRNS£5.1m funding round for Econic Technologies
17th Dec 201312:32 pmRNSResult of AGM
17th Dec 20139:00 amRNS£17.5m funding round for Crescendo Biologics
11th Dec 20137:00 amRNSIXICO launches first CE marked device
10th Dec 20137:00 amRNSSeed funding round for Cambridge spinout Aqdot
6th Dec 20137:00 amRNSGrant of share options
22nd Nov 20133:24 pmRNSOxford Immunotec trading commences on NASDAQ
20th Nov 20139:25 amRNSPulmocide receives £17m Series A funding
18th Nov 20137:00 amRNSMISSION Therapeutics receives £20m funding
16th Oct 20137:01 amRNSOxford Immunotec makes public S1 for potential IPO
16th Oct 20137:00 amRNSBoard Changes
16th Oct 20137:00 amRNSFinal Results
1st Oct 20139:00 amRNSCircassia grass allergy treatment success
26th Sep 20137:00 amRNSCell Medica opens commercial facility in Germany
23rd Sep 20137:05 amRNSIXICO expands into digital healthcare
23rd Sep 20137:00 amRNSProposed acquisition of IXICO Limited
20th Sep 20139:00 amRNSNotice of Results
12th Sep 20137:00 amRNSCircassia phase II clinical study success
10th Sep 20137:00 amRNSLeads £8m funding round in Plaxica
29th Aug 20137:00 amRNSInvestment in new mobile payments business
12th Aug 20136:01 pmRNSDirector/PDMR Shareholding
26th Jul 20138:45 amRNSPortfolio company PolyTherics merges with Antitope
17th Jul 20137:00 amRNSDirectorate Change
2nd Jul 20137:00 amRNS£30m loan from EIB for healthcare investment
25th Jun 20137:00 amRNSInvestment in PsychologyOnline
4th Jun 20137:00 amRNSAutifony starts phase I trial
8th May 20137:00 amRNSCell Medica treats first patient in new trial
29th Apr 20137:00 amRNSInvestment team appointment
17th Apr 20139:26 amRNSBoard change
22nd Mar 20137:00 amRNSHalf year results
1st Mar 20139:22 amRNSNotice of Results
1st Mar 20138:38 amRNSNotification of major interest in shares
25th Feb 20137:00 amRNSCircassia's cat allergy treatment
14th Feb 20137:00 amRNSInvestment in new technology company
23rd Jan 20137:00 amRNS£1.5m investment in new software portfolio company
21st Jan 20133:45 pmRNSListing of shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.